IP Library Granted Patent US 8,425,435
Granted Patent B2
US 8,425,435 · App. 12/794,595 · Granted Apr 23, 2013

Transducer cartridge for an ultrasound therapy head

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,425,435
App. No.
12/794,595
Granted
Apr 23, 2013
Kind
B2
Abstract

A medical ultrasound system. A base unit is included having system electronics, a user interface and ultrasound control electronics. An ultrasound therapy head is in electronic communication with the base unit. The therapy head includes a replaceable, sealed transducer cartridge with a coupling fluid therein. A cooling system is provided for cooling the coupling fluid. A plurality of guide indicators are positioned around the therapy head to align with crossed lines on a patient so as to properly align the therapy head prior to use. The therapy head can provide variable treatments to an area while the therapy head is in contact with a patient.

Claims (22)

1. A cartridge connectable to a body to form a therapy head, the body including a driver, said cartridge comprising:

an acoustic coupling liquid;

a sealed enclosure comprising a wall, an interior filled with the acoustic coupling fluid, and an exterior surface, the wall including an acoustic window and an opening sealed to prevent loss of the acoustic coupling liquid from the interior;

a high intensity ultrasound transducer within the sealed enclosure and having an output surface generally aligned with the acoustic window;

a bearing member passing through the opening in the wall and coupled to the high intensity ultrasonic transducer, said bearing member being attachable to the driver in the body to orient the direction of acoustic energy delivered through the acoustic window by the high intensity ultrasonic transducer; and

a heat exchanger thermally coupled to draw heat from the acoustic coupling liquid without removing said acoustic coupling liquid from the sealed enclosure, the heat exchanger including a conduit disposed within the interior of the sealed enclosure and connected to inlet and outlet ports formed through the wall, the conduit of the heat exchanger coiled to surround a central space defined inside the interior of the sealed enclosure, and the conduit configured to receive a cooling liquid for circulation through the conduit to cool the acoustic coupling liquid while the acoustic coupling liquid remains isolated from the cooling liquid wherein the high intensity ultrasound transducer is disposed in the central space.

2. The cartridge of claim 1 , wherein the conduit has serpentine segments to increase the heat transfer area.

3. The cartridge of claim 1 , wherein the transducer is a short stack transducer assembly.

4. The cartridge of claim 1 , wherein the acoustic coupling liquid comprises water.

5. The cartridge of claim 1 , wherein the cooling liquid comprises water.

6. The cartridge of claim 1 , further comprising:

a metallization layer coating the wall of the sealed enclosure, the metallization layer configured to reduce a gas permeability of the wall.

7. The cartridge of claim 6 , wherein the metallization layer has a thickness approximately 500 to 1500 Ångstroms.

8. The cartridge of claim 6 , wherein the metallization layer has a thickness that is less than X, where X=[((α−0.09)*1000)/0.03]+500, with X being the metallization layer thickness in Angstroms, and a being a maximum acceptable acoustic attention in dB in a transmission window.

9. The cartridge of claim 1 , wherein the acoustic coupling liquid is not circulated through the wall of the enclosed space during the operation of the high intensity ultrasound transducer.

10. The cartridge of claim 1 , wherein the acoustic coupling liquid is not circulated through the opening in the wall of the enclosed space during the operation of the high intensity ultrasound transducer.

11. The cartridge of claim 1 , wherein the acoustic coupling liquid comprises a volume of about 100 to 200 milliliters.

12. The cartridge of claim 1 , wherein the sealed enclosure is self-contained.

13. The cartridge of claim 1 , wherein the acoustic coupling liquid surrounds the high intensity ultrasound transducer and is configured to couple the acoustic energy from the high intensity ultrasound transducer for delivery through the acoustic window.

14. The cartridge of claim 1 , wherein the cartridge is removably connected to the body and is disposable upon removal from the body.

15. The cartridge of claim 1 , wherein the cartridge is removable from the body and replaceable as a single unit.

16. The cartridge of claim 1 , wherein the acoustic coupling liquid is not removed from the sealed enclosure for degassing during the operation of the high intensity ultrasound transducer.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
MERGER Recorded May 13, 2021
From: AESTHERA; LIPOSONIX, INC.
To: SOLTA MEDICAL, INC.
Reel/Frame 056227/0174 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2014
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: LIPOSONIX, INC.
Reel/Frame 032126/0370 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2014
From: SILICON VALLEY BANK
To: LIPOSONIX, INC.
Reel/Frame 032126/0531 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Nov 19, 2013
From: LIPOSONIX, INC.
To: CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; CAPITAL ROYALTY PARTNERS II L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031674/0454 →